Page last updated: 2024-12-06

beta-butyrolactone

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth

Description

beta-butyrolactone: structure [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID18303
CHEMBL ID1361205
CHEBI ID82296
MeSH IDM0061195

Synonyms (61)

Synonym
2-oxetanone, 4-methyl-
.beta.-butyrolactone
4-methyloxetan-2-one
4-methyl-2-oxetanone
einecs 221-330-3
ccris 111
einecs 253-093-7
(1)-4-methyloxetan-2-one
beta-butyrolakton [czech]
3-hydroxybutanoic acid, beta-lactone
hydroxybutyric acid lactone
3-hydroxybutyric acid lactone
beta-butyrolactone
NCGC00091733-01
3068-88-0
beta-butyrolactone, 98%
B0901
beta-methylpropiolactone
2-oxetanone, 4-methyl-, (s)-
NCGC00091733-02
C19201
unii-8bb68v31mt
beta-butyrolakton
8bb68v31mt ,
dtxcid50223
dtxsid1020223 ,
cas-3068-88-0
NCGC00256595-01
tox21_302988
tox21_201253
NCGC00258805-01
AKOS015955924
FT-0622894
dl-.beta.-butyrolactone
(+/-)-.beta.-butyrolactone
rac-.beta.-butyrolactone
beta-butyrolactone [iarc]
(+/-)-.beta.-methylpropiolactone
36536-46-6
CHEBI:82296 ,
racemic beta-butyrolactone
betabutyrolactone
CHEMBL1361205
3-hydroxybutanoic acid, .beta.-lactone
.beta.-butyrolakton
butanoic acid, 3-hydroxy-, beta-lactone
3-hydroxybutyric acid, .beta.-lactone
(+/-)-b-butyrolactone
beta-butyrolactone, analytical standard
J-018058
Q27155863
mfcd00005170
AT19323
SY310635
mfcd12827426
CS-0377913
beta-methyl-beta-propiolactone
3-hydroxybutyric acid beta-lactone
beta -butyrolactone
EN300-6940117
SY051647
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

ClassDescription
beta-lactone
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (5)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
retinoic acid nuclear receptor alpha variant 1Homo sapiens (human)Potency76.95880.003041.611522,387.1992AID1159553
estrogen nuclear receptor alphaHomo sapiens (human)Potency5.49480.000229.305416,493.5996AID743075
peroxisome proliferator activated receptor gammaHomo sapiens (human)Potency54.94770.001019.414170.9645AID743191
thyroid hormone receptor beta isoform aHomo sapiens (human)Potency1.99530.010039.53711,122.0200AID588547
survival motor neuron protein isoform dHomo sapiens (human)Potency35.48130.125912.234435.4813AID1458
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (29)

TimeframeStudies, This Drug (%)All Drugs %
pre-19904 (13.79)18.7374
1990's1 (3.45)18.2507
2000's8 (27.59)29.6817
2010's15 (51.72)24.3611
2020's1 (3.45)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other31 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]